Ultragenyx Pharmaceutical Inc.
General ticker "RARE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.4B (TTM average)
Ultragenyx Pharmaceutical Inc. does not follow the US Stock Market performance with the rate: -5.1%.
Estimated limits based on current volatility of 3.1%: low 34.17$, high 36.33$
Factors to consider:
- Total employees count: 1294 as of 2024
- North America accounted for 60.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operating losses and capital needs, Clinical development risks, Regulatory and compliance, Market competition, Supply chain disruptions
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [23.10$, 57.31$]
- 2025-12-31 to 2026-12-31 estimated range: [17.13$, 44.06$]
Financial Metrics affecting the RARE estimates:
- Negative: with PPE of -6.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.56 <= 0.33
- Positive: Inventory ratio change, % of 0.18 <= 0.84
- Negative: Shareholder equity ratio, % of 16.98 <= 18.93
- Positive: Interest expense per share per price, % of 1.61 <= 3.41
- Positive: Investing cash flow per share per price, % of -0.45 > -0.66
Short-term RARE quotes
Long-term RARE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $363.33MM | $434.25MM | $560.23MM |
| Operating Expenses | $1,012.25MM | $1,003.46MM | $1,096.20MM |
| Operating Income | $-648.92MM | $-569.21MM | $-535.97MM |
| Non-Operating Income | $-52.81MM | $-39.26MM | $-31.61MM |
| Interest Expense | $43.02MM | $66.00MM | $63.04MM |
| R&D Expense | $705.79MM | $648.45MM | $697.87MM |
| Income(Loss) | $-701.73MM | $-608.46MM | $-567.59MM |
| Taxes | $5.70MM | $-1.82MM | $1.60MM |
| Profit(Loss)* | $-707.42MM | $-606.64MM | $-569.18MM |
| Stockholders Equity | $352.49MM | $275.41MM | $255.30MM |
| Inventory | $26.77MM | $33.97MM | $45.01MM |
| Assets | $1,545.44MM | $1,491.01MM | $1,503.46MM |
| Operating Cash Flow | $-380.46MM | $-474.81MM | $-414.19MM |
| Capital expenditure | $146.12MM | $46.77MM | $7.49MM |
| Investing Cash Flow | $-291.65MM | $168.00MM | $-17.77MM |
| Financing Cash Flow | $501.21MM | $388.14MM | $399.24MM |
| Earnings Per Share** | $-10.12 | $-8.25 | $-6.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.